VLA-15 is under clinical development by Valneva and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VLA-15’s likelihood of approval (LoA) and phase transition for Lyme Disease took place on 10 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VLA-15 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VLA-15 overview

VLA-15 (IC-15) is under development for the prevention of lyme borreliosis infection. The vaccine candidate is administered through intramuscular route. It is a multivalent, outer surface protein A (OspA)-based protein subunit vaccine. It is developed based on antigen identification program technology. It is a new molecular entity.

Valneva overview

Valneva is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Chikungunya, Zika virus, and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.

Quick View VLA-15 LOA Data

Report Segments
  • Innovator
Drug Name
  • VLA-15
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Valneva
  • Originator: Intercell
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.